DelveInsight’s, “Ranibizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Ranibizumab Biosimilars landscape.
It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration, a common form of age-related vision loss.
Its effectiveness is similar to that of bevacizumab. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. It is often used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept.
Ranibizumab Biosimilars Drugs Chapters
This segment of the Ranibizumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ranibizumab Biosimilars Companies: Marketed Drugs
· Razumab: Intas Pharmaceuticals
Razumab is the tenth biosimilar launched by Intas in India, by far the largest number of indigenously developed biosimilars by any company. Since 2004, when Intas launched its first biosimilar, Intas has constantly worked to bring the latest in biological therapies to Indian patients at affordable prices. With its robust pipeline of future products under development, Intas aims to continue on this endeavor. Till date, Intas is also the only company from India to have launched a biosimilar in the highly regulated European market and is also the only company from India to have two of its biosimilars filed for registration in the US. Its first biosimilar for global markets, Accofil (filgratsim) was launched in Europe earlier this year. The company expects to launch its first biosimilar in the US within the next 9–12 months. Intas’ manufacturing facilities are approved by global regulatory agencies such as EMA, ANVISA, WHO and others.
Razumab is also manufactured in the same facilities as its other biosimilars.
Ranibizumab Biosimilars: Emerging Drugs
· SB-11: Samsung Bioepis
SB11 is a ranibizumab biosimilar candidate, to reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD). The drug is currently in phase III stage of development.
Ranibizumab: Therapeutic Assessment
This segment of the report provides insights about the different Ranibizumab biosimilars segregated based on following parameters that define the scope of the report, such as:
·
Major Players in Ranibizumab
There are approx. 20+ key companies which are developing the therapies for Ranibizumab.
· Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
· Marketed stage products
· Late stage products (BLA Filed and Phase III)
· Mid-stage products (Phase II and
· Early-stage products (Phase I) along with the details of
· Pre-clinical and Discovery stage candidates
· Discontinued & Inactive candidates
· Route of Administration
Ranibizumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
· Subcutaneous
· Intravenous
· Molecule Type
Products have been categorized under various Molecule types such as
· Monoclonal antibodies
· Peptide
· Protein
· Small molecule
· Product Type
Read More- Ranibizumab Biosimilar Guidelines